What is Nano-X Imaging?
Founded in 2011, Nano-X Imaging is an Israeli-based medical technology innovator specializing in commercial-grade digital X-ray source systems. The company's core mission is to democratize access to medical imaging by drastically reducing the capital expenditure and operational costs associated with traditional X-ray hardware. By integrating mobile app solutions into a broader diagnostic ecosystem, Nano-X Imaging facilitates early detection and preventative care on a global scale.
The company operates at the intersection of hardware engineering and digital health, targeting a market segment that has historically been constrained by high equipment costs. Their strategic focus on global partnerships across the Middle East and Asia Pacific regions demonstrates a robust operational model designed for rapid deployment and widespread clinical adoption.
How much funding has Nano-X Imaging raised?
Nano-X Imaging has raised a total of $54.9M across 4 funding rounds:
Angel/Seed
$8M
Series A
$4.9M
Series B
$12M
Series C
$30M
Angel/Seed (2015): $8M with participation from DeepFork Capital and Khosla Ventures Acquisition
Series A (2015): $4.9M led by OurCrowd
Series B (2016): $12M supported by Khosla Ventures Acquisition and Intermountain Healthcare
Series C (2018): $30M featuring NVIDIA, Dolby Family Ventures, Aurum, Johnson & Johnson InnovationJJDC Inc., Khosla Ventures Acquisition, aMoon Ventures, and OurCrowd
Key Investors in Nano-X Imaging
NVIDIA
A global leader in accelerated computing and artificial intelligence, providing the computational power necessary for advanced medical imaging and diagnostic software.
OurCrowd
A prominent global venture investment platform that provides institutional-grade access to high-growth technology startups and early-stage ventures.
Intermountain Healthcare
A leading integrated healthcare system that provides strategic insights and clinical validation for innovative medical technologies.
What's next for Nano-X Imaging?
With the recent influx of capital, Nano-X Imaging is poised to accelerate its commercialization strategy and expand its global footprint. The company is expected to prioritize the scaling of its manufacturing capabilities and the deepening of its strategic alliances with major healthcare providers. As the firm transitions into this mature growth phase, the focus will likely shift toward regulatory milestones and the integration of its imaging ecosystem into existing hospital workflows.
Investors are closely monitoring the company's ability to maintain its cost-advantage while navigating the complex regulatory landscape of international medical device markets. The continued support from high-profile institutional backers suggests a strong long-term outlook for the company's role in the future of digital health infrastructure.
